Pharma IQ Members

Sheraz
Gul

sheraz-gul

Sheraz is Head of Assay Development & Screening at the Fraunhofer Institute for Molecular Biology and Applied Ecology – ScreeningPort. In his role, he is responsible for the management and development of Assay Development and Medium and High Throughput Screening activities for partners across the world. He has 23 years’ experience in both academia (University of London) and industry (GlaxoSmithKline Pharmaceuticals). This has ranged from the detailed study of catalysis by biological catalysts (enzymes and catalytic antibodies) to the design and development of assays for High Throughput Screening for the major drug target classes. He is the co-author of numerous papers, chapters and the Enzyme Assays: Essential Data handbook.

He now works for the Fraunhofer Institute - one of the largest applied research organisations in Europe employing around 23,000 staff.  

Safeguarding of information that the pharmaceutical industry disseminates via social media is essential. Although pharmaceutical industry websites contain a wealth of useful information, there appears to be a general apprehension in their use to disseminate medically relevant information...Full Article »
Open Source initiatives have proliferated across many areas of research including drug discovery. The surge in their popularity has been largely attributed to their benefits of enabling open collaboration between multiple parties. As Open Source for drug discovery continues to increase and diversify, it will be useful to understand its potential...Full Article »
Cloud computing is likely to become an essential technology in the pharmaceutical industry. While some of the purported benefits such as the computer-aided screening are not likely to transform the pharmaceutical industry, its many other advantages such as the ability to afford a potentially vast amount of computational power will remain crucial...Full Article »
Columnist Sheraz Gul shares highlights of the recent 8th Annual Smartlabs Exchange. The main themes included the future of lab informatics, implementing solutions to improve efficiency, data integration and smart knowledge sharing, enabling a more efficient lab....Full Article »
We are currently witnessing an expansion in the disciplines encompassing drug discovery outside the pharmaceutical industry. This is most notable with a significant number of Universities worldwide now hosting infrastructures such as compound libraries and automated screening systems....Full Article »
Sheraz Gul reviews the recent 11th Annual ELNs & Advanced Laboratory Solutions Conference, which recently took place in Milan...Full Article »
The pre-clinical phase of drug discovery  involves many years of research being conducted by multi-disciplinary teams. These teams will generate significant amounts of data which are processed using standard as well as specialist software.  Traditionally, most of the information generated would typically be recorded using paper-based...Full Article »
Dr. Sheraz Gul, VP and Head of Biology at European ScreeningPort speaks candidly to Pharma IQ about moving onto a new informatics platform, explains the steps they are taking to ensure a smooth integration...Full Article »